Efficacy of Bydureon in Adults with Type 2 Diabetes

• Main Author: Fetter, Katie L.
• Format: Others
• Published: UNF Digital Commons 2014
• Subjects: Thesis; University of North Florida; UNF; Dissertations; Academic > UNF > Master of Science in Nursing; Academic > UNF > Nursing; Bydureon; Type 2 Diabetes; GLP 1 receptor agonist; Glucagon-like peptide 1 > Effectiveness > Testing; Non-insulin-dependent diabetes > Treatment > Testing; Family Practice Nursing; Medicine and Health Sciences; Nursing
• Online Access: http://digitalcommons.unf.edu/etd/490; http://digitalcommons.unf.edu/cgi/viewcontent.cgi?article=1525&context=etd

Type 2 diabetes is still rapidly on the rise today, affecting 10.5% of individuals in the United States between the ages 45 to 64 and 18.4% of those between the ages of 65 to 74. In the past two decades, type 2 diabetes has doubled in all age groups. Many adults with type 2 diabetes experience difficulty managing their blood sugars, which can result in a range of further complications. One of the newest treatment options on the market today is a glucagon-like peptide-1 (GLP-1) receptor agonist, Bydureon. Similar to Byetta, Bydureon has a main ingredient of exenatide. It offers once a week dosing as opposed to twice-a-day, which may be more appealing to patients. The purpose of this study was to examine the efficacy of a newly FDA released medication, Bydureon, once weekly dosage in adults with type 2 diabetes. A descriptive, comparative, retrospective study of 35 patients evaluated efficacy by examining Hgb A1C and body mass index in adults with type 2 diabetes at baseline and 3 months after Bydureon was prescribed. Data were collected by a chart review of records in a primary care practice. Results demonstrated a statistically significant difference between baseline to 3 month means in both Hgb A1C (t (34)= -3.05, p=.0044) and BMI (t (34) = -2.86, p = .0072) for patients using Bydureon. Health care providers need to individualize the patients’ plans of care to address multifactorial areas of their diabetes care and provide them with an opportunity to successfully meet their goals. Practitioners must be knowledgeable about the treatment options available, including the newer GLP-1 receptor agonist, Bydureon and its efficacy for adults with type 2 diabetes.